| Title |
Fibrolamellar hepatocellular carcinoma: current clinical perspectives
|
|---|---|
| Published in |
Journal of Hepatocellular Carcinoma, October 2015
|
| DOI | 10.2147/jhc.s75153 |
| Pubmed ID | |
| Authors |
Kelly J Lafaro, Timothy M Pawlik |
| Abstract |
Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ∼1%-9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10-35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 20% |
| Researcher | 7 | 16% |
| Student > Bachelor | 5 | 11% |
| Student > Doctoral Student | 3 | 7% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 6 | 14% |
| Unknown | 11 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 41% |
| Biochemistry, Genetics and Molecular Biology | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Agricultural and Biological Sciences | 3 | 7% |
| Computer Science | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 11 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 August 2016.
All research outputs
#20,657,128
of 25,374,917 outputs
Outputs from Journal of Hepatocellular Carcinoma
#161
of 262 outputs
Outputs of similar age
#210,057
of 286,877 outputs
Outputs of similar age from Journal of Hepatocellular Carcinoma
#4
of 4 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 262 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,877 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.